>
Switch to:

Adaptive Biotechnologies Cash-to-Debt

: 5.51 (As of Jun. 2021)
View and export this data going back to 2019. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Adaptive Biotechnologies's cash to debt ratio for the quarter that ended in Jun. 2021 was 5.51.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Adaptive Biotechnologies could pay off its debt using the cash in hand for the quarter that ended in Jun. 2021.

The historical rank and industry rank for Adaptive Biotechnologies's Cash-to-Debt or its related term are showing as below:

NAS:ADPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.51   Med: 16.89   Max: No Debt
Current: 5.51

5.51
No Debt

During the past 4 years, Adaptive Biotechnologies's highest Cash to Debt Ratio was No Debt. The lowest was 5.51. And the median was 16.89.

NAS:ADPT's Cash-to-Debt is ranked lower than
64% of the 1472 Companies
in the Biotechnology industry.

( Industry Median: 13.85 vs. NAS:ADPT: 5.51 )

Adaptive Biotechnologies Cash-to-Debt Historical Data

The historical data trend for Adaptive Biotechnologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20
Cash-to-Debt
No Debt No Debt 15.76 6.38

Adaptive Biotechnologies Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.47 18.02 6.38 7.17 5.51

Competitive Comparison

For the Biotechnology subindustry, Adaptive Biotechnologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Adaptive Biotechnologies Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Cash-to-Debt falls into.



Adaptive Biotechnologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Adaptive Biotechnologies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2020 is calculated as:

Adaptive Biotechnologies's Cash to Debt Ratio for the quarter that ended in Jun. 2021 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adaptive Biotechnologies  (NAS:ADPT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Adaptive Biotechnologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptive Biotechnologies Business Description

Adaptive Biotechnologies logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2836
Traded in Other Exchanges
Address
1551 Eastlake Avenue East, Suite 200, Seattle, WA, USA, 98102
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Executives
Benzeno Sharon officer: Chief Business Development Off C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102
Robins Harlan S officer: Chief Scientific Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102
Hershberg Robert director 3005 FIRST AVENUE SEATTLE WA 98121
Lo Francis officer: Chief People Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102
Griffin Michelle Renee director 19723 NE 65TH LANE KIRKLAND WA 98033
Pellini Michael J director 222 DUTTON MILL RD WILLISTOWN PA 19380
Cohen Chad M officer: Chief Financial Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVENUE E STE 200 SEATTLE WA 98101
Baldo Lance officer: Chief Medical Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102
Robins Chad M director, officer: CEO and Chairman C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102
Dobmeier Eric director C/O SAETTLE GENETICS INC 21823 30TH DRIVE SE BOTHELL WA 98021
Rubinstein Julie officer: President C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102
Bobulsky Susan officer: SVP, Diagnostics, clonoSEQ C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102
Taylor Stacy L officer: SVP and General Counsel C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVENUE E SUITE 200 SEATTLE WA 98102
Sang Charles officer: SVP, External Affairs C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102
Hill Nancy Louise officer: EVP, Operations & Program Mana C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102

Adaptive Biotechnologies Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)